Therapy Areas: Cardiovascular
Rexgenero Names Jones as a Non-Executive Director
14 February 2020 - - Dr Huw Jones has joined UK-based regenerative medicine company Rexgenero's board as a non-executive director, and will chair the company's remuneration committee, the company said.

This follows the appointment earlier this week of Dr David Horn Solomon as chairman of Rexgenero's Board.

Huw is currently CEO of Chronos Therapeutics Ltd. (Chronos), a spin out from the University of Oxford, UK focused on the development of a therapies for behavioural brain diseases.

He has completed a transformation of Chronos, including extracting the company from the university, restructuring the organisation and completing the acquisition of an early brain disease development portfolio from Shire PLC (now part of Takeda).

Huw was recently voted European CEO of the Year, Drug Discovery by print and online publication European CEO Magazine, alongside industry leaders from companies such as Adidas, Unilever and Spotify in their respective sectors.

Huw is also CEO of Gen2 Neuroscience Ltd., a company based in Cambridge, UK focused on tauopathies via interference with specific toxic types of extracellular tau. Gen2 is funded by the UK Dementia Discovery Fund.

Huw has held a number of senior leadership roles at pharmaceutical and biotech companies and founded strategy consultancy Daffodil Consulting LLP.

Prior roles include non-executive director and then CEO of Ardana PLC; president, Europe for NASDAQ-quoted cardiovascular company CV Therapeutics Inc.; non-executive chairman of UK speciality pharma company Ashbourne Pharmaceuticals; and SVP Northern Europe at Elan Pharmaceuticals.

He started his career at SmithKline Beecham (now part of Glaxo SmithKline PLC), where he was appointed in a number of commercial and business development roles of increasing responsibility over a decade.

Huw holds a PhD in Pharmacology from the University of Birmingham, UK.

Rexgenero is a privately held, UK-based regenerative medicine company pioneering the development of patient-specific cell-based therapies to treat serious diseases such as chronic limb-threatening ischemia.

Rexgenero's lead product, REX-001, consists of a suspension of immune and progenitor cells involved in immune modulation, blood vessel regeneration and remodelling and improvement in blood flow.

It is manufactured using a patient's own cells, avoiding undesired immune responses.

REX-001 is currently being tested in two pivotal, placebo-controlled, double-blind, adaptive Phase III SALAMANDER trials in patients with CLI and diabetes mellitus at multiple sites across Europe.

Previous randomised REX-001 clinical trials have already demonstrated statistically significant proof of concept.

In a Phase I/II and Phase II clinical trial, REX-001 showed very strong positive results in improvement of blood flow, healing of ulcers and alleviating chronic ischemic rest pain.

All ulcers healed within 12 months in 82% of patients after treatment with REX-001 at the dose being currently tested in Phase III trials.

Rexgenero was incorporated in 2015 using therapies that were developed by the Andalusian Health Authority and Andalusian Initiative of Advanced Therapies, world experts in the development of advanced cell and gene therapies.

This partnership and Rexgenero's leading expertise in cell therapy clinical development, manufacturing and biology is a major platform for development of new therapies and continued leadership in advanced therapies.

Rexgenero has offices in London, UK and R and D and manufacturing operations in Seville, Spain and additional manufacturing capability in Frankfurt, Germany.

Rexgenero is planning to treat a total of 60 diabetic patients with CLI and rest pain and 78 diabetic patients with CLI and non-healing ischemic ulcers in two independent Phase III SALAMANDER trials in approximately 30 hospitals across Europe.

The trials are given the name SALAMANDER in reference to the amphibian's ability to regenerate cells in its tail and limbs.
Login
Username:

Password: